دورية أكاديمية
أعرض في EDS

Gliclazide in Binary and Ternary Systems Improves Physicochemical Properties, Bioactivity, and Antioxidant Activity.

التفاصيل البيبلوغرافية
العنوان: Gliclazide in Binary and Ternary Systems Improves Physicochemical Properties, Bioactivity, and Antioxidant Activity.
المؤلفون: Ibrahim M; Department of Biochemistry, Bahauddin Zakariya University, Multan 60800, Pakistan., Munir S; Department of Biochemistry, Bahauddin Zakariya University, Multan 60800, Pakistan., Ahmed S; Department of Basic Sciences, University of Veterinary and Animal Sciences Lahore, Narowal Campus, Narowal 51600, Pakistan., Chughtai AH; Institute of Chemical Sciences, Bahauddin Zakariya University, Multan 60800, Pakistan., Ahmad W; Department of Clinical Sciences, University of Veterinary and Animal Sciences Lahore, Narowal Campus, Narowal 51600, Pakistan., Khan J; Department of Chemistry, Khwaja Fareed University of Engineering & Information Technology, Rahim Yar Khan 64200, Pakistan., Murtey MD; Basic Sciences and Oral Biology Unit, School of Dental Sciences, Health Campus, Universiti Sains Malaysia, Kubang Kerian 16150, Kelantan, Malaysia., Ijaz H; Department of Pharmacy, Pak-Austria Fachhochschule Institute of Applied Sciences and Technology, Mang, Haripur 22620, Khyber Pakhtunkhwa, Pakistan., Ojha SC; Department of Infectious Diseases, The Affiliated Hospital of Southwest Medical University, Luzhou 646000, China.; Southwest Medical University, Jiangyang District, Luzhou 646000 Sichuan, China.
المصدر: Oxidative medicine and cellular longevity [Oxid Med Cell Longev] 2022 Nov 25; Vol. 2022, pp. 2100092. Date of Electronic Publication: 2022 Nov 25 (Print Publication: 2022).
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: Hindawi Pub. Corp Country of Publication: United States NLM ID: 101479826 Publication Model: eCollection Cited Medium: Internet ISSN: 1942-0994 (Electronic) Linking ISSN: 19420994 NLM ISO Abbreviation: Oxid Med Cell Longev Subsets: MEDLINE
أسماء مطبوعة: Publication: 2011- : New York : Hindawi Pub. Corp.
Original Publication: 2008-2010: Austin, TX : Landes Bioscience
مواضيع طبية MeSH: Gliclazide*/pharmacology, Animals ; Antioxidants/pharmacology ; 2-Hydroxypropyl-beta-cyclodextrin ; Hypoglycemic Agents/pharmacology ; Hypoglycemic Agents/therapeutic use ; Solubility
مستخلص: The poor solubility of the antidiabetic drug gliclazide (Glc) is due to its hydrophobic nature. This research is aimed at improving Glc's solubility and drug release profile, as well as at investigating additional benefits such as bioactivity and antioxidant activity, by forming binary complexes with HP β CD at different w / w ratios (1 : 1, 1 : 2.5, 1 : 4, and 1 : 9) and ternary complexes with HP β CD and Tryp at 1 : 1 : 1, 1 : 1 : 0.27, 1 : 2.5 : 0.27, 1 : 3.6 : 3.6, 1 : 4 : 1, and 1 : 9 : 1, respectively. Complexes were prepared by the physical mixing (PM) and solvent evaporation (SE) methods. The prepared inclusion complexes were meticulously characterized by X-ray diffractometry (XRD), scanning electron microscopy (SEM), and attenuated total reflectance-Fourier transform infrared (ATR-FTIR) spectra. To verify our findings, the inclusion complexes were evaluated by equilibrium solubility, in vitro drug release profile, kinetic models, and antidiabetic and antioxidant activities in animal models. Our results demonstrated that the solubility and drug release profile were found to be enhanced through binary as well as ternary complexes. Notably, ternary complexes with a ratio of 1 : 9 : 1 showed the highest solubility and drug release profile compared to all other preparations. Data on antioxidant activity indicated that the ternary complex had the higher total antioxidant status (TAS), superoxide dismutase (SOD), and catalase (CAT) activity than the binary complex and Glc alone, in contrast to the diabetic group. In vivo antidiabetic activity data revealed a high percentage reduction in the blood glucose level by ternary complexes (49-52%) compared to the binary complexes (45-46%; p ≤ 0.05). HP β CD and Tryp provide a new platform for overcoming the challenges associated with poorly soluble Glc by providing greater complexing and solubilizing capabilities and imparting ancillary benefits to improve the drug's antidiabetic and antioxidant activities.
Competing Interests: The authors declare no conflict of interests.
(Copyright © 2022 Muhammad Ibrahim et al.)
References: Pak J Pharm Sci. 2011 Oct;24(4):459-68. (PMID: 21959805)
Redox Rep. 2018 Dec;23(1):1-24. (PMID: 28514939)
J Pharm Biomed Anal. 2015 Sep 10;113:226-38. (PMID: 25743620)
J Biol Chem. 1952 Mar;195(1):133-40. (PMID: 14938361)
Mol Cell Biochem. 2006 Oct;291(1-2):101-5. (PMID: 16715184)
J Pharm Biomed Anal. 2004 Apr 1;35(1):75-86. (PMID: 15030882)
Diabetologia. 2008 Feb;51(2):216-26. (PMID: 18087688)
Chem Cent J. 2014 Mar 11;8(1):17. (PMID: 24618480)
J Pharm Sci. 1997 Jan;86(1):1-12. (PMID: 9002452)
Eur J Pharm Biopharm. 2013 Nov;85(3 Pt B):873-81. (PMID: 23537574)
Pharm Dev Technol. 2018 Dec;23(10):1007-1015. (PMID: 27885872)
Adv Drug Deliv Rev. 2007 Jul 30;59(7):667-76. (PMID: 17618704)
J Agric Food Chem. 2021 Jun 2;69(21):5871-5881. (PMID: 34013730)
Eur J Pharmacol. 2018 Sep 15;835:31-40. (PMID: 30075220)
Cardiovasc Hematol Agents Med Chem. 2019;17(1):40-46. (PMID: 31124426)
Clin Biochem. 2004 Feb;37(2):112-9. (PMID: 14725941)
Pharmaceutics. 2014 Jul 14;6(3):416-35. (PMID: 25025400)
Endocr Res. 2005;31(3):199-212. (PMID: 16392622)
AAPS PharmSciTech. 2008;9(2):563-70. (PMID: 18459056)
Spectrochim Acta A Mol Biomol Spectrosc. 2007 May;67(1):230-4. (PMID: 16950645)
Int J Pharm. 2004 Mar 19;272(1-2):1-10. (PMID: 15019063)
Pharm Dev Technol. 2017 Feb;22(1):69-76. (PMID: 27050301)
Arch Pharm Res. 2011 May;34(5):757-65. (PMID: 21656361)
Carbohydr Polym. 2012 Nov 6;90(4):1719-24. (PMID: 22944438)
Int J Pharm. 2006 Feb 17;309(1-2):129-38. (PMID: 16377107)
Int J Pharm. 2021 Apr 1;598:120363. (PMID: 33556487)
J Pharm Pharmacol. 2010 Nov;62(11):1607-21. (PMID: 21039545)
Colloids Surf B Biointerfaces. 2021 May;201:111625. (PMID: 33621750)
Biochemistry. 1992 Dec 22;31(50):12543-5. (PMID: 1472491)
المشرفين على المادة: G4PX8C4HKV (Gliclazide)
0 (Antioxidants)
1I96OHX6EK (2-Hydroxypropyl-beta-cyclodextrin)
0 (Hypoglycemic Agents)
تواريخ الأحداث: Date Created: 20221205 Date Completed: 20221206 Latest Revision: 20221206
رمز التحديث: 20221206
مُعرف محوري في PubMed: PMC9718633
DOI: 10.1155/2022/2100092
PMID: 36466089
قاعدة البيانات: MEDLINE
الوصف
تدمد:1942-0994
DOI:10.1155/2022/2100092